United Therapeutics (UTHR) is back in focus after the FDA granted premarket approval for its LungFX device, a centralized ex vivo lung perfusion system that supports donor lung evaluation before transplantation.

Beyond LungFX, United Therapeutics has stayed active, from sponsorship of National Patch Day to recent index changes. The stock’s 1 day share price return of 1.60% and 1 year total shareholder return of 88.77% indicate momentum that appears to have built over time rather than faded in recent months.

If LungFX has you thinking about where medical technology could go next, it may be worth seeing what other healthcare related AI opportunities are emerging through our 40 healthcare AI stocks

With United Therapeutics now trading at $555.91, showing a 1 year total return of 88.77% and an intrinsic value estimate implying a large theoretical discount, the key question is whether there is still an opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 16.4% Undervalued

At a last close of $555.91 versus a narrative fair value of $665.23, United Therapeutics is framed as materially undervalued, with that gap hinging on how its pipeline and earnings power play out over time.

The analysts have a consensus price target of $665.23 for United Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $750.0 and the most bearish reporting a price target of just $516.0.

Want to see what underpins that fair value gap on United Therapeutics? The narrative leans on projected revenue growth, margin resilience and a future earnings multiple that has been carefully dialed back. Curious which specific assumptions and timeframes do the heavy lifting in that model?

Result: Fair Value of $665.23 (UNDERVALUED)

However, the United Therapeutics narrative can still be knocked off course if key trials disappoint or if pulmonary competition and pricing pressure turn out to be more intense than expected.

Next Steps

If this all sounds optimistic around United Therapeutics, take a moment to pressure test the story yourself, act promptly while sentiment stays strong, and then weigh those signals against the 3 key rewards

Looking for more investment ideas beyond United Therapeutics?

If United Therapeutics has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas that could reshape how you think about opportunity and risk.

Use the Simply Wall Street Screener now to uncover fresh stock ideas before they slip past you.

• Target dependable income by reviewing companies that qualify as 7 dividend fortresses and see which yields stand out for you.
• Hunt for mispriced potential with the screener containing 18 high quality undiscovered gems and spot quality businesses that may not be widely followed yet.
• Prioritize resilience by scanning the 75 resilient stocks with low risk scores and quickly see which stocks line up with your comfort on downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.